General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-12 | 2024-06 | 0 | N/A | N/A | N/A |
2024-05-20 | 2024-03 | 0 | -0.17 | N/A | N/A |
2024-04-02 | 2023-12 | 0 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -8.96 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -134.33 | N/A | N/A |
2023-05-22 | 2023-03 | 0 | -526.87 | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-04-20 | GLAZER CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-05-09 | PALELLA SALVATORE | Chief Executive Officer | 240.30K | Purchase |
2022-11-13 | PROFUMO GIULIO | Chief Financial Officer | 51.50K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Virtu Financial LLC | 164.56K | 18.51K | 0.07% |
2023-06-29 | Cubist Systematic Strategies, LLC | 87.92K | 9.89K | 0.04% |
2023-06-29 | Millennium Management Llc | 96.44K | 10.85K | 0.04% |
2023-06-29 | Vanguard Group Inc | 74.38K | 8.37K | 0.03% |
2023-06-29 | Baader Bank Aktiengesellschaft | 51.00K | 5.74K | 0.02% |
2023-06-29 | Geode Capital Management, LLC | 46.18K | 5.19K | 0.02% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 74.38K | 8.37K | 0.03% |
2023-05-30 | Fidelity Extended Market Index Fund | 27.50K | 9.40K | 0.01% |
Split | Date |
---|---|
1 : 150 | 2023-12-04 |
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $13 Price Target
3 weeks ago, November 15, 2023 at 10:24 AM EST
Via Analyst Upgrades
ACXP
Share
HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals with a Buy and maintains $13 price target.
look also ACXP 100% approved
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure
All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure (CC) at end of treatment (EOT) remained free of C. difficile Infection (CDI) recurrence through one month after EOT, for a Sustained Clinical Cure (SCC) rate of 100%
2 of 14 patients treated with standard of care, oral vancomycin, experienced recurrent infection within one month after EOT for a SCC of 86%
10
News
$Micromobility.com (MCOM.US)$ micromobility.com Inc. Slashes Debt by $9.25 Million in Strategic Financial Triumph
1 MINUTE AGO, 7:25 AM EST
VIA BUSINESSWIRE
Just now Announced
micromobility.com Inc. Slashes Debt by $9.25 Million in Strategic Financial Triumph
7 minutes ago, 7:25 AM EST
Via BusinessWire
MCOM
Share
micromobility.com Inc. (NASDAQ:MCOM) announces a landmark achievement in its financial strategy, significantly reducing its debt and setting a course for profitability. The Company has successfully implemented a Settlement and Release Agreement, leading to a major reduction in its debt burden.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211437447/en/
$MCOM check $KTRA
In with 270k… just waiting
$MCOM 100million volume before 10 come on let’s send this!!
$MCOM check WAVD
$MCOM check $WAVD
$MCOM check $WAVD
$MCOM
$MCOM curling up